Recent News

• 10.28.2025 - October 2025 – BioTuesdays
• 09.28.2025 - Atebimetinib (IMM-1-104) + Modified Gemcitabine/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results
• 09.26.2025 - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
• 09.26.2025 - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
• 09.25.2025 - Phase 2a Data Update for IMM-1-104 in First-Line Pancreatic Cancer
• 09.25.2025 - Phase 2a Data Update for IMM-1-104 in First-Line Pancreatic Cancer
• 09.25.2025 - Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
• 09.25.2025 - Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Recent Filings

• 10.21.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.03.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]